Quest Diagnostics has launched LeukoVantage, a testing service to aid doctors in the diagnosis, prognosis, and monitoring of myeloid cancers, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasm.
Quest said LeukoVantage complements standard diagnostic techniques. The test employs next-generation sequencing, PCR, and other methods to gauge mutations in 30 genes linked to myeloid neoplasms and to quickly diagnose patients in the early stages of disease, monitor minimal residual disease, and direct them to targeted drugs such as JAK2 inhibitors.
According to Quest, LeukoVantage can detect genetic mutations in greater than 95 percent of newly diagnosed AML cases. The firm also highlighted LeukoVantage's potential to guide treatment decisions with epigenetic modifying drugs for AML and MDS patients.